BRAZE INC-A (BRZE) Fundamental Analysis & Valuation

NASDAQ:BRZE • US10576N1028

Current stock price

18.97 USD
-1.71 (-8.27%)
At close:
19.1 USD
+0.13 (+0.69%)
After Hours:

This BRZE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BRZE Profitability Analysis

1.1 Basic Checks

  • BRZE had positive earnings in the past year.
  • BRZE had a positive operating cash flow in the past year.
  • BRZE had negative earnings in each of the past 5 years.
  • In multiple years BRZE reported negative operating cash flow during the last 5 years.
BRZE Yearly Net Income VS EBIT VS OCF VS FCFBRZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 2026 0 50M -50M -100M

1.2 Ratios

  • The Return On Assets of BRZE (-11.79%) is worse than 65.82% of its industry peers.
  • The Return On Equity of BRZE (-21.05%) is worse than 60.73% of its industry peers.
Industry RankSector Rank
ROA -11.79%
ROE -21.05%
ROIC N/A
ROA(3y)-13.21%
ROA(5y)-14.17%
ROE(3y)-23.99%
ROE(5y)-23.7%
ROIC(3y)N/A
ROIC(5y)N/A
BRZE Yearly ROA, ROE, ROICBRZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30 -40

1.3 Margins

  • BRZE has a Gross Margin of 67.15%. This is comparable to the rest of the industry: BRZE outperforms 47.64% of its industry peers.
  • In the last couple of years the Gross Margin of BRZE has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for BRZE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y1.05%
BRZE Yearly Profit, Operating, Gross MarginsBRZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 2026 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BRZE Health Analysis

2.1 Basic Checks

  • BRZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BRZE has more shares outstanding
  • BRZE has more shares outstanding than it did 5 years ago.
  • BRZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRZE Yearly Shares OutstandingBRZE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
BRZE Yearly Total Debt VS Total AssetsBRZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.16 indicates that BRZE is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.16, BRZE is in line with its industry, outperforming 58.91% of the companies in the same industry.
  • BRZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 2.16
ROIC/WACCN/A
WACC10.96%
BRZE Yearly LT Debt VS Equity VS FCFBRZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 2026 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.35 indicates that BRZE should not have too much problems paying its short term obligations.
  • BRZE has a Current ratio of 1.35. This is comparable to the rest of the industry: BRZE outperforms 42.18% of its industry peers.
  • A Quick Ratio of 1.35 indicates that BRZE should not have too much problems paying its short term obligations.
  • BRZE's Quick ratio of 1.35 is in line compared to the rest of the industry. BRZE outperforms 42.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
BRZE Yearly Current Assets VS Current LiabilitesBRZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BRZE Growth Analysis

3.1 Past

  • BRZE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 111.11%, which is quite impressive.
  • Looking at the last year, BRZE shows a very strong growth in Revenue. The Revenue has grown by 24.40%.
  • The Revenue has been growing by 37.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)24.4%
Revenue growth 3Y27.59%
Revenue growth 5Y37.5%
Sales Q2Q%27.91%

3.2 Future

  • Based on estimates for the next years, BRZE will show a very strong growth in Earnings Per Share. The EPS will grow by 48.87% on average per year.
  • Based on estimates for the next years, BRZE will show a quite strong growth in Revenue. The Revenue will grow by 16.50% on average per year.
EPS Next Y69.85%
EPS Next 2Y62.53%
EPS Next 3Y51.8%
EPS Next 5Y48.87%
Revenue Next Year21.43%
Revenue Next 2Y19.16%
Revenue Next 3Y18.4%
Revenue Next 5Y16.5%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BRZE Yearly Revenue VS EstimatesBRZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BRZE Yearly EPS VS EstimatesBRZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

3

4. BRZE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 49.92, which means the current valuation is very expensive for BRZE.
  • The rest of the industry has a similar Price/Earnings ratio as BRZE.
  • BRZE's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.78.
  • The Price/Forward Earnings ratio is 29.39, which means the current valuation is very expensive for BRZE.
  • BRZE's Price/Forward Earnings is on the same level as the industry average.
  • When comparing the Price/Forward Earnings ratio of BRZE to the average of the S&P500 Index (23.54), we can say BRZE is valued slightly more expensively.
Industry RankSector Rank
PE 49.92
Fwd PE 29.39
BRZE Price Earnings VS Forward Price EarningsBRZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • BRZE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 37.06
EV/EBITDA N/A
BRZE Per share dataBRZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • BRZE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BRZE's earnings are expected to grow with 51.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.71
PEG (5Y)N/A
EPS Next 2Y62.53%
EPS Next 3Y51.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BRZE Dividend Analysis

5.1 Amount

  • BRZE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRZE Fundamentals: All Metrics, Ratios and Statistics

BRAZE INC-A

NASDAQ:BRZE (4/10/2026, 8:08:56 PM)

After market: 19.1 +0.13 (+0.69%)

18.97

-1.71 (-8.27%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-24
Earnings (Next)06-03
Inst Owners75.21%
Inst Owner Change0.02%
Ins Owners11.1%
Ins Owner Change48.99%
Market Cap2.15B
Revenue(TTM)738.18M
Net Income(TTM)-131.29M
Analysts85.19
Price Target35.75 (88.46%)
Short Float %10.72%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.98%
Min EPS beat(2)-28.83%
Max EPS beat(2)-5.12%
EPS beat(4)2
Avg EPS beat(4)101.81%
Min EPS beat(4)-28.83%
Max EPS beat(4)391.01%
EPS beat(8)6
Avg EPS beat(8)185.33%
EPS beat(12)10
Avg EPS beat(12)138.78%
EPS beat(16)14
Avg EPS beat(16)109.91%
Revenue beat(2)2
Avg Revenue beat(2)1.56%
Min Revenue beat(2)1.48%
Max Revenue beat(2)1.64%
Revenue beat(4)4
Avg Revenue beat(4)1.76%
Min Revenue beat(4)0.14%
Max Revenue beat(4)3.8%
Revenue beat(8)8
Avg Revenue beat(8)1.31%
Revenue beat(12)12
Avg Revenue beat(12)1.8%
Revenue beat(16)16
Avg Revenue beat(16)2.02%
PT rev (1m)-18.28%
PT rev (3m)-24.94%
EPS NQ rev (1m)-9.2%
EPS NQ rev (3m)-10.2%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)4.02%
Revenue NQ rev (3m)4.02%
Revenue NY rev (1m)3.51%
Revenue NY rev (3m)3.51%
Valuation
Industry RankSector Rank
PE 49.92
Fwd PE 29.39
P/S 2.92
P/FCF 37.06
P/OCF 30.13
P/B 3.45
P/tB 7.16
EV/EBITDA N/A
EPS(TTM)0.38
EY2%
EPS(NY)0.65
Fwd EY3.4%
FCF(TTM)0.51
FCFY2.7%
OCF(TTM)0.63
OCFY3.32%
SpS6.51
BVpS5.5
TBVpS2.65
PEG (NY)0.71
PEG (5Y)N/A
Graham Number6.86
Profitability
Industry RankSector Rank
ROA -11.79%
ROE -21.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.15%
FCFM 7.87%
ROA(3y)-13.21%
ROA(5y)-14.17%
ROE(3y)-23.99%
ROE(5y)-23.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y1.05%
F-Score4
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 69.14%
Cap/Sales 1.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z 2.16
F-Score4
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)143.07%
Cap/Depr(5y)189.8%
Cap/Sales(3y)2.5%
Cap/Sales(5y)2.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y69.85%
EPS Next 2Y62.53%
EPS Next 3Y51.8%
EPS Next 5Y48.87%
Revenue 1Y (TTM)24.4%
Revenue growth 3Y27.59%
Revenue growth 5Y37.5%
Sales Q2Q%27.91%
Revenue Next Year21.43%
Revenue Next 2Y19.16%
Revenue Next 3Y18.4%
Revenue Next 5Y16.5%
EBIT growth 1Y-9.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year225.57%
EBIT Next 3Y92.91%
EBIT Next 5Y84.49%
FCF growth 1Y195.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.76%
OCF growth 3YN/A
OCF growth 5YN/A

BRAZE INC-A / BRZE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BRAZE INC-A?

ChartMill assigns a fundamental rating of 4 / 10 to BRZE.


Can you provide the valuation status for BRAZE INC-A?

ChartMill assigns a valuation rating of 3 / 10 to BRAZE INC-A (BRZE). This can be considered as Overvalued.


Can you provide the profitability details for BRAZE INC-A?

BRAZE INC-A (BRZE) has a profitability rating of 1 / 10.


What are the PE and PB ratios of BRAZE INC-A (BRZE) stock?

The Price/Earnings (PE) ratio for BRAZE INC-A (BRZE) is 49.92 and the Price/Book (PB) ratio is 3.45.


How financially healthy is BRAZE INC-A?

The financial health rating of BRAZE INC-A (BRZE) is 6 / 10.